ArcherDX recently said it received FDA breakthrough device designation for its next-generation sequencing device. The NGS device is designed as a companion diagnostic to detect neurotrophic receptor tyrosine kinase gene fusions that can lead to the formation and growth of cancer. ArcherDX’s technology uses Multiplex PCR chemistry that captures DNA, RNA or ctDNA from blood […]
ArcherDX
ArcherDX wins breakthrough nod for personalized cancer monitoring tech
ArcherDX announced that it has won breakthrough device designation from the FDA for its personalized cancer monitoring (PCM) technology. Boulder, Colo.-based ArcherDX’s PCM platform is designed for minimally invasive monitoring and recurrence surveillance for early-stage cancer treatment. It is meant to offer healthcare providers access to genomic information in their laboratory. ArcherDX also recently won […]